The most prevalent and dangerous disease in herds that raise calves is bovine respiratory disease (BRD). In the US, the antibiotic ceftiofur, a third-generation cephalosporin, is authorized for use in cattle. The purpose of this study was to investigate the biochemical changes caused by the BRD and the effectiveness of ceftiofur.
On a dairy farm, thirty Holstein calves were split up into three groups. Group I served as a constructively critical group. Group II consisted of healthy animals that received a single subcutaneous ear injection of ceftiofur (2 mg/kg B.W.) Group III, clinically investigated to be suffering from BRD, was given ceftiofur with the same dose and administration route as group II. After taking drugs, all groups underwent clinical evaluations for sickness scores on days 0, 7, and 14. 
Biochemical examination revealed a large rise in globulin and a significant decrease in total proteins and albumin (P<0.05) on days 0 and 7^th where globulin levels increased significantly (P<0.05) on day 14^th, elevated liver enzyme levels and renal function tests in the diseased treated group. In comparison to the control group, the biochemical values in the healthy treatment group did not alter significantly. In conclusion, the research results showed that a number of biochemical markers were significantly impacted by respiratory disorders in calves. Because ceftiofur had a high rate of success, minimal negative effects on clinical indicators, and an appropriate dose and administration schedule, it may be the prescribed medication for BRD.